

Representative Steve Eliason proposes the following substitute bill:

UNDIAGNOSED CHILDREN INSURANCE COVERAGE

AMENDMENTS

2019 GENERAL SESSION

STATE OF UTAH

Chief Sponsor: Steve Eliason

Senate Sponsor: David G. Buxton

LONG TITLE

General Description:

This bill requires the state Medicaid program and Public Employees' Benefit and Insurance Program to cover exome sequence testing.

Highlighted Provisions:

This bill:

- defines terms; and
- requires the state Medicaid program and Public Employees' Benefit and Insurance Program to cover exome sequence testing for certain enrollees.

Money Appropriated in this Bill:

None

Other Special Clauses:

None

Utah Code Sections Affected:

ENACTS:

26-18-25, Utah Code Annotated 1953

49-20-419, Utah Code Annotated 1953



26 *Be it enacted by the Legislature of the state of Utah:*

27 Section 1. Section **26-18-25** is enacted to read:

28 **26-18-25. Coverage of exome sequence testing.**

29 (1) As used in this section, "exome sequence testing" means a genomic technique for
30 sequencing the genome of an individual for diagnostic purposes.

31 (2) The Medicaid program shall reimburse for exome sequence testing:

32 (a) for an enrollee who:

33 (i) is younger than 21 years of age; and

34 (ii) who remains undiagnosed after exhausting all other appropriate diagnostic-related
35 tests;

36 (b) performed by a nationally recognized provider with significant experience in exome
37 sequence testing;

38 (c) that is medically necessary; and

39 (d) at a rate set by the Medicaid program.

40 Section 2. Section **49-20-419** is enacted to read:

41 **49-20-419. Coverage of exome sequence testing.**

42 (1) As used in this section, "exome sequence testing" means a genomic technique for
43 sequencing the genome of an individual for diagnostic purposes.

44 (2) Beginning July 1, 2019, the program shall provide coverage for exome sequence
45 testing:

46 (a) for a covered individual within the state risk pool who:

47 (i) is younger than 21 years of age; and

48 (ii) who remains undiagnosed after exhausting all other appropriate diagnostic-related
49 tests;

50 (b) performed by a nationally recognized provider with significant experience in exome
51 sequence testing;

52 (c) that is medically necessary; and

53 (d) at a rate set by the program.